• Explore /
  • Poster
  • / SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.

SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.

Abstract Poster

Authors

null

Yongheng Liu

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China

Yongheng Liu , Wei Lian , Xi Zhao , Yina Diao , Jian Xu , Liang Xiao , Yan Qing , Tongtong Xue , Jingyi Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT04152499

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS3659)

DOI

10.1200/JCO.2020.38.15_suppl.TPS3659

Abstract #

TPS3659

Poster Bd #

389

Abstract Disclosures

Similar Posters

First Author: Wenfeng Fang

First Author: Frederick M. Dirbas

First Author: Vivek Subbiah

First Author: Miao Wang